Author + information
To evaluate the effect and safety by observed the patients’ NYHA classification, echocardiography, heartrate, blood pressure, peripheral venous pressure, Liver and renal fuction, NT-proBNP before and after used Levosimendan.
(1)Choose patients: From January 2016 to Oct 2016,total 24 patients were selected in Shenyang military region general hospital. All the patients had no medicine contraindication. (2)Treatment: All the patients received the standard treatment aiming at heart failure. The drugs included of diuretic, ACEI, beta blockers and digoxin. On the basis of the treatments above, used the intravenous Levosimendan (0.1ug/kg.min total 12.5mg). (3)Observe the patients’ NYHA classification, echocardiography, heart rate, blood pressure, peripheral venous pressure, Liver and renal fuction, NT-proBNP before and after used Levosimendan.
The patients were male 16,female 8. After the use of Levosimendan:2h,4h,8h,16h,24h,48h,72h,96h,the change of heart rate and blood pressure had no statistically significant difference(P>0.05). After the medicine in 5 days, the difference like Liver and renal function had no statistically significant (P0.05). The median of NT-proBNP levels were 6565.5(2308,9800)pg/ml before treatment. It recover to 860(480,1780)pg/ml after the treatment. The patients’ NYHA classification, echocardiography, heart rate, peripheral venous pressure were improved (P<0.05).
Patients like structural heart disease could use the intravenous Levosimendan. During the treatment, the heart rate and blood pressure, Liver and renal function had no significant changed. Many other index were improved. This kind of patients using intravenous Levosimendan were effectively and safety.